BridgeBio Pharma (BBIO) Net Equity Issued and Repurchased (2018 - 2024)
BridgeBio Pharma (BBIO) posted Net Equity Issued and Repurchased of -$18000.0 for Q3 2024, down 100.05% sequentially from $38.2 million in Q2 2024, and down 100.01% YoY from $241.3 million in Q4 2023.
BridgeBio Pharma (BBIO) Net Equity Issued and Repurchased (2018 - 2024) Analysis & Trends
BridgeBio Pharma has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at -$18000.0 in Q3 2024.
- Quarterly Net Equity Issued and Repurchased fell 100.01% year-over-year to -$18000.0 in Q3 2024, while the trailing twelve-month figure through Jun 2025 was -$18000.0 (down 100.0% YoY) and the FY2024 annual result came in at $314.7 million, down 30.03% from the prior year.
- Net Equity Issued and Repurchased declined to -$18000.0 in Q3 2024 per BBIO's latest filing, from $38.2 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $315.3 million in Q1 2024 and troughed at -$454000.0 in Q4 2023.
- A 3-year average of $92.9 million and a median of $21.5 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased plunged 109.27% in 2023, then soared 3594.0% in 2024.
- Over 3 years, Net Equity Issued and Repurchased stood at $4.9 million in 2022, then slumped by 109.27% to -$454000.0 in 2023, then soared by 96.04% to -$18000.0 in 2024.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$18000.0, $38.2 million, and $315.3 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | BridgeBio Pharma | 15.60 Bn | 14.89 Bn | 228.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -18,000.00 |
| Sep 30, 2024 | -18,000.00 |
| Jun 30, 2024 | 38.16 Mn |
| Jun 30, 2024 | 38.16 Mn |
| Mar 31, 2024 | 315.25 Mn |
| Mar 31, 2024 | 315.25 Mn |
| Dec 31, 2023 | -454,000.00 |
| Dec 31, 2023 | -454,000.00 |
| Sep 30, 2023 | 241.30 Mn |
| Sep 30, 2023 | 241.30 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 143.02 Mn |
| Mar 31, 2023 | 143.02 Mn |
| Dec 31, 2022 | 4.90 Mn |
| Dec 31, 2022 | 4.90 Mn |
| Dec 31, 2018 | 239.46 Mn |
| Dec 31, 2018 | 239.46 Mn |
| Sep 30, 2018 | -1.19 Mn |
| Sep 30, 2018 | -1.19 Mn |